Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.31 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201511 | 0.86 | NPC1 (0.37) | NPC1RAB9A | |
| SCHEMBL202304 | 0.84 | NPC1 (0.39) | NPC1RAB9ATNKS2MAPTPKM | |
| SCHEMBL202491 | 0.83 | PCSK9 (0.43) | NPC1RAB9ATNKS2MAPTPKM | |
| SCHEMBL2707355 | 0.83 | NPC1 (0.38) | NPC1RAB9ATNKS2MAPTPKM | |
| SCHEMBL203165 | 0.80 | NPC1 (0.43) | NPC1RAB9AMAPTPKMSMN1; SMN2 | |
| SCHEMBL202801 | 0.80 | NPC1 (0.47) | NPC1RAB9AMAPTPKMSMN1; SMN2 | |
| SCHEMBL201488 | 0.80 | NPC1 (0.43) | NPC1RAB9ATNKS2MAPTPKM | |
| SCHEMBL204150 | 0.79 | NPC1 (0.46) | NPC1RAB9AMAPTPKMSMN1; SMN2 | |
| SCHEMBL14421920 | 0.79 | NPC1 (0.47) | NPC1RAB9AMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL2707340 | 0.78 | NPC1 (0.38) | NPC1RAB9ATNKS2MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | NPC1 2815/4885RAB9A 1213/4885ADORA2A 4538/4885 |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | NPC1 1400/4885RAB9A 2799/4885ADORA2A 4510/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | NPC1 1786/4885RAB9A 1340/4885ADORA2A 4518/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | NPC1 1400/4885RAB9A 2799/4885ADORA2A 4510/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | NPC1 1400/4885RAB9A 2799/4885ADORA2A 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.